New Insights on Leqembi®: Three-Year Real-World Data Unveiled at CTAD 2026

Unveiling New Data on Leqembi® at CTAD 2026



In a landmark presentation at the 19th Clinical Trials on Alzheimer's Disease (CTAD) in Boston, BioArctic AB and its partner Eisai revealed novel findings from the real-world Lecanemab study focusing on early Alzheimer's Disease (AD). The study, known as LEADER, demonstrated an astonishing 76% reduction in the advancement to moderate or severe Alzheimer's dementia for patients treated with Leqembi over a 36-month period compared to control groups.

This significant revelation was based on an analysis of 560 patients treated at 13 clinical sites across the United States. Representing the most extensive data compilation from the ongoing LEADER study, these results reinforce the effectiveness of Leqembi in practical applications, including aspects such as disease progression, amyloid clearance, treatment persistence, and safety.

Key Findings from the LEADER Study


The LEADER study's results offer compelling insights:
  • - Slower Progression of Disease: A notable comparison within the data showed that patients in the LEADER cohort (504 patients) exhibited a significantly slower decline when juxtaposed with a control group from the Alzheimer's Disease Neuroimaging Initiative (ADNI). The findings indicated a Hazard Ratio (HR) of 0.24, underscoring the impact of Leqembi in preventing rapid disease progression.
  • - Patient Stability: Impressively, over 80% of participants reported stability or improvement in their AD status after approximately 18 months of treatment.
  • - High Treatment Adherence: At the time of data extraction, a staggering 87.5% of patients continued their Leqembi treatment, indicating promising treatment adherence over an average duration of 19 months.

Insights on Amyloid Clearance


Moreover, the research also showcased significant advancements in amyloid clearance among patients. Among 43 individuals who underwent both pre- and post-treatment amyloid PET scans, 77% demonstrated complete amyloid negativity at a median follow-up of 18 months. This clearance may correlate with the observed cognitive stability and potential improvements amongst patients.

Expansion of Maintenance Treatment Options


As part of transitioning treatment strategies, the study also highlighted the effective implementation of maintenance therapies. Of the patients who achieved an 18-month treatment milestone, 91.7% proceeded to remain on Leqembi for ongoing management. This includes a transition of 218 patients to intravenous (IV) maintenance treatments while 64 patients began new once-weekly subcutaneous (SC) treatments.

Focus on Safety and Tolerability


The safety profile of Leqembi was also a focal point of the findings, with no major adverse reactions (ARIA) reported during the SC maintenance period. Issues like isolated ARIA-H were relatively rare (0.5%) during the IV maintenance period. This showcases a favorable safety landscape in real-world settings, consistent across both male and female patients.

Future Implications in Alzheimer’s Care


Looking forward, the implications of these findings could potentially reshape approaches to Alzheimer's care, especially with Leqembi approved in 53 countries and under review in six more regions. As a pioneering drug in slowing the progression of early Alzheimer's disease, Leqembi’s integration into treatment regimens may enhance outcomes for countless individuals suffering from this debilitating condition.

The collaboration between BioArctic and Eisai continues to flourish, marking a significant step forward in the battle against Alzheimer's disease. The ongoing Phase 3 studies (AHEAD 3-45), targeting preclinical Alzheimer’s patients, further emphasize the commitment to advancing therapeutic options for neurodegenerative disorders. As patient data expands and research continues, Leqembi stands at the forefront of innovative treatments poised to alter the landscape of Alzheimer’s care for the better.

Conclusion


In summary, the presentation at CTAD 2026 not only highlights the remarkable efficacy of Leqembi but underlines a collective commitment to understanding and treating Alzheimer’s disease through robust research and clinical practice. This event marks a promising horizon for both patients and caregivers navigating the complexities of Alzheimer's management.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.